KMDA

KMDA

USD

Kamada Ltd. Ordinary Shares

$6.670-0.220 (-3.193%)

Цена в режиме реального времени

Healthcare
Drug Manufacturers - Specialty & Generic
Израиль

График цен

Loading Chart...

Ключевые показатели

Рыночные показатели
Фундаментальные показатели компании
Статистические данные торговли

Рыночные показатели

Открытие

$6.890

Максимум

$6.890

Минимум

$6.660

Объем

0.03M

Фундаментальные показатели компании

Рыночная капитализация

386.0M

Отрасль

Drug Manufacturers - Specialty & Generic

Страна

Israel

Статистические данные торговли

Средний объем

0.06M

Биржа

NMS

Валюта

USD

52-недельный диапазон

Минимум $5.54Текущая $6.670Максимум $9.15

Отчет об анализе ИИ

Последнее обновление: 13 окт. 2025 г.
Сгенерировано ИИИсточник данных: Yahoo Finance, Bloomberg, SEC

KMDA's Pulse Quickens: Data Points to a Short-Term Surge for Kamada

October 13, 2025, 08:31 AM EDT

Whispers in the Headlines

The news stream around Kamada has been quiet lately, but the key events from late summer tell an important story. Back on August 11th, the company announced a solid operational win: FDA approval for its new plasma collection center in Houston. This is a tangible piece of good news that expands the company's capacity. Just two days later, the company held its Q2 earnings call. While the transcript itself is just a record, the timing is interesting. That day, August 13th, saw a huge spike in trading volume and a wide price swing, suggesting the market was reacting strongly to the financial results and commentary. These past events seem to be setting the stage for the current market mood.

The Anatomy of a Downturn

Looking at Kamada's stock chart over the last three months is like watching a slow, grinding descent. The shares tumbled from a peak above $8.00 in mid-July, falling steadily through August and September. The price eventually found a floor, bouncing multiple times in the $6.50 to $6.70 range. This area appears to be a new level of support where buyers have consistently stepped in.

The most recent price action shows a potential change in character. After hitting a low of $6.50 on October 7th, the stock has started to claw its way back up, closing the latest session at $6.80. This stabilization, after a long period of selling, is often the first sign that the balance of power might be shifting from sellers back to buyers.

The Digital Crystal Ball

The current technical picture is where things get compelling. Several indicators are flashing green, suggesting a bullish turn. We're seeing a "golden cross" in the MACD indicator, a classic signal that momentum is shifting upward. Trading volume has also surged, which confirms there's real conviction behind the recent price moves. On top of that, our AI model is forecasting a price jump of nearly 4% over the next three days with a high degree of confidence.

However, it's important to weigh this against the company's financial health. The fundamental data points to some real challenges, including very high debt and low revenue growth. This creates a clear conflict: the short-term technicals and AI predictions look strong, but the long-term business fundamentals appear weak. This suggests any current opportunity is likely a short-term trade, not a long-term investment.

The Bottom Line

For traders with a moderate appetite for risk, the data suggests a short-term opportunity in Kamada (KMDA) may be forming. The combination of a potential bottom in the stock price, strong technical buy signals, and a bullish AI forecast creates a compelling case for a quick trade over the next one to two weeks. The weak fundamentals, however, mean this is not a "buy and hold" situation.

A strategic approach could involve entering a position around the $6.77 - $6.83 levels. Given the stock's recent volatility and underlying risks, setting a firm stop-loss at $6.12 is critical to protect against a reversal. If the bullish momentum continues as the data suggests, a reasonable target to take profits would be near $7.29.


Disclaimer: This report is for informational purposes only and does not constitute financial advice, an offer to sell, or a solicitation of an offer to buy any security. The analysis is based solely on the structured data provided and may not be comprehensive. Investing in stocks involves risks, including the possible loss of principal. You should always conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Связанные новости

GlobeNewswire

Kamada Reports Strong Third Quarter and Nine Month 2025 Financial Results with over 30% Year-over-Year Profitability Growth

Third Quarter Revenues of $47.0 Million, up 13% Year-over-Year, and Adjusted EBITDA of $11.7 Million, up 34% Year-Over YearNine Month Revenue of $135.8 Million, up 11% Year-over-Year; Adjusted EBITDA of $34.2 Million, up

Просмотреть больше
Kamada Reports Strong Third Quarter and Nine Month 2025 Financial Results with over 30% Year-over-Year Profitability Growth
GlobeNewswire

Kamada to Announce Third Quarter and Nine Months Ended September 30, 2025 Financial Results on November 10, 2025

REHOVOT, Israel and HOBOKEN, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for

Просмотреть больше
Kamada to Announce Third Quarter and Nine Months Ended September 30, 2025 Financial Results on November 10, 2025
GlobeNewswire

Kamada to Present at the Stifel 2025 Healthcare Conference

REHOVOT, Israel and Hoboken, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious

Просмотреть больше
Kamada to Present at the Stifel 2025 Healthcare Conference

Прогноз ИИBeta

Рекомендация ИИ

Бычий

Обновлено в: 10 нояб. 2025 г., 12:05

МедвежийНейтральныйБычий

65.5% Уверенность

Риск и торговля

Уровень риска3/5
Средний риск
Подходит для
Умеренный
Руководство по торговле

Точка входа

$6.61

Взять прибыль

$7.17

Остановить убытки

$6.02

Ключевые факторы

RSI на уровне 71.4 указывает на условия перекупленности
PDI 13.8 выше MDI 5.4 с ADX 11.8, что предполагает бычий тренд
Текущая цена очень близка к уровню поддержки ($6.61), что предполагает сильную возможность покупки
Объем торгов в 2.6 раз превышает среднее значение (1,593), демонстрируя значительный покупательский интерес
MACD 0.0059 выше сигнальной линии -0.0033, что указывает на бычье пересечение

Оставаться в курсе

Установите ценовой сигнал, получите обновления анализа ИИ и новости рынка в режиме реального времени.